Welcome to our dedicated page for Alignment Healthcare SEC filings (Ticker: ALHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alignment Healthcare, Inc.'s SEC filings document a Medicare Advantage operating company with common stock listed on Nasdaq under ALHC. Its Form 8-K reports furnish quarterly and annual operating results, health plan membership, revenue, adjusted gross profit, adjusted EBITDA, guidance updates and Regulation FD materials related to strategy, market position and Medicare Advantage quality ratings.
Proxy materials cover board elections, executive compensation, equity awards, pay-versus-performance data and shareholder voting matters. Registration statements, prospectus supplements and underwriting agreements describe secondary offerings of common stock by selling stockholders, the company's capital structure and related securities-law obligations.
Alignment Healthcare, Inc. director and Chief Executive Officer John E. Kao reported open-market sales of a total of 250,000 shares of Common Stock on April 7, 2026, through indirect holdings. The sales occurred at weighted-average prices of $20.67 and $21.3953 per share.
The indirectly held shares are owned by the JEK Trust, dated February 8, 2021, for which Mr. Kao serves as trustee. After these transactions, he continues to hold 2,104,641 shares indirectly and 1,784,868 shares directly. The sales were made pursuant to a Rule 10b5-1 trading plan adopted on November 21, 2025.
ALHC affiliate reported proposed and recent sales of Common Stock, including a listed block of 548,000 shares. The filing lists multiple completed sales under a 10b5-1 Sales Plan on dates in 2026 (for example, 180,000 on 03/10/2026 and 118,000 on 03/23/2026) and shows a reference outstanding figure of 204,296,493 as of 04/07/2026.
Alignment Healthcare, Inc. notification of proposed insider sale of 27,198 shares of Common Stock acquired on 06/04/2025 through the vesting of restricted stock units under the Issuer's 2021 Equity Incentive Plan. The securities are listed on the Nasdaq Stock Market. The filing is a Form 144 notice dated 04/07/2026.
Alignment Healthcare, Inc. reported that Chief Legal and Admin. Officer Christopher J. Joyce sold 18,013 shares of common stock in an open-market transaction. The weighted-average sale price was $17.7923 per share, within a range of $17.57 to $17.99. Following this sale, he directly holds 305,451 shares. The transaction was executed pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on 09/08/2025.
Morgan Stanley Smith Barney LLC Executive Financial Services filed a Form 144 disclosing proposed sales of 35,736 shares of Common stock by Christopher J. Joyce. The filing lists two transactions: 10,611 shares sold on 01/02/2026 for $212,590.32 and 25,125 shares sold on 03/18/2026 for $448,230.00. The record notes 10b5-1 sales and shows awards classified as Performance Stock Units and Restricted Stock Units with grant dates and share counts.
Alignment Healthcare Inc filing: The Vanguard Group submitted Amendment No. 4 to a Schedule 13G/A reporting beneficial ownership of 0 shares representing 0% of Alignment Healthcare common stock. The filing explains an internal realignment by The Vanguard Group effective January 12, 2026 that led certain subsidiaries to report ownership separately.
Alignment Healthcare, Inc. director and Chief Executive Officer John E. Kao reported an open-market sale of 118,000 shares of Common Stock at a weighted-average price of $17.4783 per share. The sale was effected indirectly through JEK Trust, dated February 8, 2021, for which he serves as trustee, under a Rule 10b5-1 trading plan adopted on November 21, 2025. Following the transaction, indirect holdings through the trust were 2,354,641 shares, and a separate holding entry shows 1,784,868 shares held directly.
ALHC reported Form 144 sales by or for John E. Kao under 10b5-1 plans. The excerpt lists multiple reported dispositions of Common stock, including sales of $1,133,514.66 across transactions on 12/29/2025 and repeated sales of $3,273,558.00 and similar amounts in early 2026. The filings show routine plan-based sales rather than corporate actions.
Alignment Healthcare COO Sebastian Burzacchi reported an open-market sale of 15,361 shares of common stock. The shares were sold at a weighted-average price of $17.84 per share, in multiple trades between $17.40 and $18.24. According to the disclosure, the sale was required to cover tax withholding obligations tied to the vesting of restricted stock units and is described as non-discretionary. After this transaction, Burzacchi directly holds 258,630 shares.
Alignment Healthcare, Inc. Chief Medical Officer Hyong Kim reported an open-market sale of 18,404 shares of common stock at a weighted-average price of $17.84 per share. According to the filing, these shares were sold solely to cover tax withholding obligations from vesting restricted stock units and did not represent a discretionary trade.
After this transaction, Kim directly holds 367,701 shares of Alignment Healthcare common stock. The shares were sold in multiple trades at prices ranging from $17.40 to $18.24 per share.